|
시장보고서
상품코드
1424030
피브레이트계 약제 시장 점유율, 규모, 동향, 산업 분석 보고서 : 약물별, 제품 유형별, 형태별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)Fibrate Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug (Clofibrate, Gemfibrozil, Fenofibrate, Others); By Product Type; By Form; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면, 세계 피브레이트계 약제 시장 규모는 2032년까지 50억 4,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.
운동 부족, 생활습관 변화, 담배와 알코올 소비 증가 등의 요인이 성인 인구의 콜레스테롤 이상 위험을 증가시키고 있습니다. 예를 들어 세계보건기구(WHO)에 따르면 2023년 7월 담배로 인해 매년 800만 명 이상이 사망하고 있습니다. 이것은 심장병의 위험을 증가시킵니다. 또한 관상동맥질환, 심장마비, 말초동맥질환 등 심혈관계 질환을 앓고 있는 환자가 증가하면서 피브레이트계 약제에 대한 수요를 주도하고 있습니다.
중성지방, 저밀도 지단백(LDL) 콜레스테롤, 고밀도 지단백(HDL) 콜레스테롤과 같은 지질 불균형을 초래하는 이상지질혈증은 예측 기간 동안 피브레이트계 약제의 필요성을 증가시킬 것으로 보입니다. 예를 들어, 2022년 9월에는 인도인 10명 중 6명이 콜레스테롤 수치에 이상이 있을 것으로 예상됩니다. 이러한 콜레스테롤 수치 이상은 예측 기간 동안 피브레이트계 약제에 대한 수요를 증가시킬 것으로 보입니다.
당뇨병과 체내 LDL, HDL, 중성지방 등 지질 변화의 연관성이 시장 성장에 기여하고 있습니다. 따라서 당뇨병 환자가 증가함에 따라 피브레이트계 약제에 대한 수요도 예측 기간 동안 증가할 것입니다. 예를 들어, 국제당뇨병연맹(IDF)에 따르면 2021년 인도에는 7억 7,420만 명의 성인이 당뇨병을 앓고 있으며, 유병률은 8.3%에 달할 것으로 예상됩니다. 또한, 시장 관계자들이 콜레스테롤 이상에 대한 새롭고 효과적인 치료법을 개발하고 출시하는 데 지속적으로 집중하고 있는 것은 향후 몇 년 동안 피브레이트계 약제 시장의 성장을 촉진할 것으로 보입니다.
피브레이트계 약제 시장 보고서 하이라이트
페노피브레이트계 약제는 중성지방 및 LDL 콜레스테롤 수치를 낮추는 높은 효과로 인해 큰 성장이 예상됩니다.
각 사가 보유한 강력한 특허 포트폴리오로 인해 브랜드 부문이 시장을 독점하고 있습니다.
정제 부문은 유효 성분의 유효기간이 길고 고용량 투여가 가능하기 때문에 가장 큰 시장 점유율을 차지하고 있습니다.
병원 및 소매 약국 부문은 입원 환자 수 증가로 인해 가장 큰 시장 점유율을 차지했습니다.
북미는 관상동맥성 심장질환의 부담이 크고 콜레스테롤 이상 발생률이 높아지면서 시장을 독점하고 있습니다.
시장 기업으로는 Viatris Inc., Aurobindo Pharma, Lupin Pharmaceuticals, Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., ANI Pharmaceuticals, Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 피브레이트계 약제 시장에 관한 인사이트
- 피브레이트계 약제 - 업계 현황
- 피브레이트계 약제 시장 역학
- 성장 촉진요인과 기회
- 저밀도 리포단백질(LDL) 레벨 증가에 따른 높은 리스크가 시장 성장을 크게 추진
- 세계에서 당뇨병 유병률이 증가하고 있어, 피브레이트계 약제 수요가 증가할 것으로 예상
- 성장 억제요인과 과제
- 대체 치료 선택사항 이용 가능성에 의해 피브레이트계 약제 수요가 제한
- 성장 촉진요인과 기회
- PESTLE 분석
- 피브레이트계 약제 업계 동향
- 밸류체인 분석
- COVID-19 감염증의 영향 분석
제5장 세계의 피브레이트계 약제 시장, 약제별
- 주요 조사 결과
- 서론
- 클로피브레이트
- 겜피브로질
- 페노피브레이트
- 기타
제6장 세계의 피브레이트계 약제 시장, 제품 유형별
- 주요 조사 결과
- 서론
- 브랜드
- 제네릭
제7장 세계의 피브레이트계 약제 시장, 형태별
- 주요 조사 결과
- 서론
- 캡슐
- 태블릿
제8장 세계의 피브레이트계 약제 시장, 유통 채널별
- 주요 조사 결과
- 서론
- 병원 및 소매 약국
- 온라인 약국
제9장 세계의 피브레이트계 약제 시장, 지역별
- 주요 조사 결과
- 서론
- 피브레이트계 약제 시장 평가, 지역별, 2019-2032년
- 피브레이트계 약제 시장 - 북미
- 북미 : 피브레이트계 약제 시장, 약제별, 2019-2032년
- 북미 : 피브레이트계 약제 시장, 유통 채널별, 2019-2032년
- 북미 : 피브레이트계 약제 시장, 제품 유형별, 2019-2032년
- 북미 : 피브레이트계 약제 시장, 형태별, 2019-2032년
- 피브레이트계 약제 시장 - 미국
- 피브레이트계 약제 시장 - 캐나다
- 피브레이트계 약제 시장 - 유럽
- 유럽 : 피브레이트계 약제 시장, 약제별, 2019-2032년
- 유럽 : 피브레이트계 약제 시장, 유통 채널별, 2019-2032년
- 유럽 : 피브레이트계 약제 시장, 제품 유형별, 2019-2032년
- 유럽 : 피브레이트계 약제 시장, 형태별, 2019-2032년
- 피브레이트계 약제 시장 - 영국
- 피브레이트계 약제 시장 - 프랑스
- 피브레이트계 약제 시장 - 독일
- 피브레이트계 약제 시장 - 이탈리아
- 피브레이트계 약제 시장 - 스페인
- 피브레이트계 약제 시장 - 네덜란드
- 피브레이트계 약제 시장 - 러시아
- 피브레이트계 약제 시장 - 아시아태평양
- 아시아태평양 : 피브레이트계 약제 시장, 약제별, 2019-2032년
- 아시아태평양 : 피브레이트계 약제 시장, 유통 채널별, 2019-2032년
- 아시아태평양 : 피브레이트계 약제 시장, 제품 유형별, 2019-2032년
- 아시아태평양 : 피브레이트계 약제 시장, 형태별, 2019-2032년
- 피브레이트계 약제 시장 - 중국
- 피브레이트계 약제 시장 - 인도
- 피브레이트계 약제 시장 - 일본
- 피브레이트계 약제 시장 - 말레이시아
- 피브레이트계 약제 시장 - 인도네시아
- 피브레이트계 약제 시장 - 한국
- 피브레이트계 약제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 피브레이트계 약제 시장, 약제별, 2019-2032년
- 중동 및 아프리카 : 피브레이트계 약제 시장, 유통 채널별, 2019-2032년
- 중동 및 아프리카 : 피브레이트계 약제 시장, 제품 유형별, 2019-2032년
- 중동 및 아프리카 : 피브레이트계 약제 시장, 형태별, 2019-2032년
- 피브레이트계 약제 시장 - 사우디아라비아
- 피브레이트계 약제 시장 - 남아프리카공화국
- 피브레이트계 약제 시장 - 이스라엘
- 피브레이트계 약제 시장 - 아랍에미리트
- 피브레이트계 약제 시장 - 라틴아메리카
- 라틴아메리카 : 피브레이트계 약제 시장, 약제별, 2019-2032년
- 라틴아메리카 : 피브레이트계 약제 시장, 유통 채널별, 2019-2032년
- 라틴아메리카 : 피브레이트계 약제 시장, 제품 유형별, 2019-2032년
- 라틴아메리카 : 피브레이트계 약제 시장, 형태별, 2019-2032년
- 피브레이트계 약제 시장 - 멕시코
- 피브레이트계 약제 시장 - 브라질
- 피브레이트계 약제 시장 - 아르헨티나
제10장 경쟁 상황
- 확장과 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- AbbVie Inc.
- Ajanta Pharma Inc
- ANI Pharmaceuticals, Inc
- Aurobindo Pharma
- Cipla
- Lupin Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Group
The global fibrate drugs market size is expected to reach USD 5.04 billion by 2032, according to a new study by Polaris Market Research. The report "Fibrate Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug (Clofibrate, Gemfibrozil, Fenofibrate, Others); By Product Type; By Form; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Factors such as lack of physical exercise, lifestyle changes, and rising consumption of tobacco & alcohol are increasing the risks of cholesterol abnormalities among the adult population. For instance, according to the World Health Organization (WHO), in July 2023, tobacco kills more than 8 million people each year. This increases the risk of heart disease. Moreover, an increasing number of patients suffering from cardiovascular diseases such as coronary artery diseases, heart attacks, and peripheral artery diseases is driving the demand for fibrate drugs.
Dyslipidemia leading to the imbalance of lipids such as triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol will increase the need for fibrate drugs over the forecast period. For instance, in September 2022, 6 in 10 Indians have abnormal levels of cholesterol. Such abnormalities associated with the levels of cholesterol will increase the demand for fibrate drugs over the forecast period.
The link between diabetes and changes in the amount of lipids such as LDL, HDL, and triglycerides in the body is contributing to the market growth. Thus, with the increasing number of patients who have diabetes, the demand for fibrate drugs will also augment over the forecast timeframe. For instance, according to the International Diabetes Federation (IDF), in India, adults who have diabetes were 774.2 Mn in 2021, with a prevalence rate of 8.3%. Furthermore, the constant focus of the market players on the development and launch of new and effective treatment options for cholesterol abnormalities will drive the growth of the fibrate drugs market in the upcoming years.
Fibrate Drugs Market Report Highlights
The fenofibrate segment is expected to witness significant growth, owing to the high efficacy of the drug in reducing triglyceride levels and LDL cholesterol.
The branded segment dominated the market, owing to the strong patent portfolio owned by various companies in the market.
The tablets segment accounted for the largest market share, owing to its longer shelf life and ability to accommodate higher active ingredient doses.
Hospital & retail pharmacy segment held the largest market share, owing to the increasing number of hospital admissions.
North America dominated the market, owing to the high burden of coronary heart disease and rising incidence of cholesterol abnormalities.
The market players include Viatris Inc., Aurobindo Pharma, Lupin Pharmaceuticals, Inc., AbbVie Inc., Sun Pharmaceutical Industries Ltd., ANI Pharmaceuticals, Inc.
Polaris Market Research has segmented the fibrate drugs market report based on drug, product type, form, distribution channel, and region:
Fibrate Drugs, Drug Outlook (Revenue - USD Billion, 2019 - 2032)
- Clofibrate
- Gemfibrozil
- Fenofibrate
- Others
Fibrate Drugs, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Branded
- Generic
Fibrate Drugs, Form Outlook (Revenue - USD Billion, 2019 - 2032)
- Capsule
- Tablet
Fibrate Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
- Hospital & Retail Pharmacy
- Online Pharmacy
Fibrate Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Fibrate Drugs Market Insights
- 4.1. Fibrate Drugs - Industry Snapshot
- 4.2. Fibrate Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. High risk associated with the increased levels of low-density lipoproteins (LDL) will significantly drive the market growth
- 4.2.1.2. The increasing prevalence of diabetes worldwide is expected to boost the demand for fibrate drugs
- 4.2.2. Restraints and Challenges
- 4.2.2.1. The availability of alternate treatment options is limiting the demand for fibrate drugs
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Fibrate Drugs Industry Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Fibrate Drugs Market, by Drug
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 5.3. Clofibrate
- 5.3.1. Global Fibrate Drugs Market, by Clofibrate, by Region, 2019-2032 (USD Billion)
- 5.4. Gemfibrozil
- 5.4.1. Global Fibrate Drugs Market, by Gemfibrozil, by Region, 2019-2032 (USD Billion)
- 5.5. Fenofibrate
- 5.5.1. Global Fibrate Drugs Market, by Fenofibrate, by Region, 2019-2032 (USD Billion)
- 5.6. Others
- 5.6.1. Global Fibrate Drugs Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Fibrate Drugs Market, by Product Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 6.3. Branded
- 6.3.1. Global Fibrate Drugs Market, by Branded, by Region, 2019-2032 (USD Billion)
- 6.4. Generic
- 6.4.1. Global Fibrate Drugs Market, by Generic, by Region, 2019-2032 (USD Billion)
7. Global Fibrate Drugs Market, by Form
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 7.3. Capsule
- 7.3.1. Global Fibrate Drugs Market, by Capsule, by Region, 2019-2032 (USD Billion)
- 7.4. Tablet
- 7.4.1. Global Fibrate Drugs Market, by Tablet, by Region, 2019-2032 (USD Billion)
8. Global Fibrate Drugs Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3. Hospital & Retail Pharmacy
- 8.3.1. Global Fibrate Drugs Market, by Hospital & Retail Pharmacy, by Region, 2019-2032 (USD Billion)
- 8.4. Online Pharmacy
- 8.4.1. Global Fibrate Drugs Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)
9. Global Fibrate Drugs Market, by Geography
- 9.1. Key findings
- 9.2. Introduction
- 9.2.1. Fibrate Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
- 9.3. Fibrate Drugs Market - North America
- 9.3.1. North America: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.3.2. North America: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.3. North America: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.3.4. North America: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.3.5. Fibrate Drugs Market - U.S.
- 9.3.5.1. U.S.: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.3.5.2. U.S.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.5.3. U.S.: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.3.5.4. U.S.: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.3.6. Fibrate Drugs Market - Canada
- 9.3.6.1. Canada: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.3.6.2. Canada: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.3.6.3. Canada: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.3.6.4. Canada: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4. Fibrate Drugs Market - Europe
- 9.4.1. Europe: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.2. Europe: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.3. Europe: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.4. Europe: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.5. Fibrate Drugs Market - UK
- 9.4.5.1. UK: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.5.2. UK: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.5.3. UK: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.5.4. UK: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.6. Fibrate Drugs Market - France
- 9.4.6.1. France: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.6.2. France: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.6.3. France: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.6.4. France: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.7. Fibrate Drugs Market - Germany
- 9.4.7.1. Germany: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.7.2. Germany: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.7.3. Germany: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.7.4. Germany: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.8. Fibrate Drugs Market - Italy
- 9.4.8.1. Italy: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.8.2. Italy: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.8.3. Italy: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.8.4. Italy: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.9. Fibrate Drugs Market - Spain
- 9.4.9.1. Spain: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.9.2. Spain: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.9.3. Spain: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.9.4. Spain: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.10. Fibrate Drugs Market - Netherlands
- 9.4.10.1. Netherlands: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.10.2. Netherlands: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.10.3. Netherlands: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.10.4. Netherlands: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.4.11. Fibrate Drugs Market - Russia
- 9.4.11.1. Russia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.4.11.2. Russia.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.4.11.3. Russia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.4.11.4. Russia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5. Fibrate Drugs Market - Asia Pacific
- 9.5.1. Asia Pacific: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.2. Asia Pacific: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.3. Asia Pacific: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.4. Asia Pacific: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5.5. Fibrate Drugs Market - China
- 9.5.5.1. China: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.5.2. China.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.5.3. China: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.5.4. China: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5.6. Fibrate Drugs Market - India
- 9.5.6.1. India: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.6.2. India.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.6.3. India: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.6.4. India: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5.7. Fibrate Drugs Market - Japan
- 9.5.7.1. Japan: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.7.2. Japan.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.7.3. Japan: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.7.4. Japan: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5.8. Fibrate Drugs Market - Malaysia
- 9.5.8.1. Malaysia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.8.2. Malaysia.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.8.3. Malaysia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.8.4. Malaysia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5.9. Fibrate Drugs Market - Indonesia
- 9.5.9.1. Indonesia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.9.2. Indonesia.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.9.3. Indonesia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.9.4. Indonesia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.5.10. Fibrate Drugs Market - South Korea
- 9.5.10.1. South Korea: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.5.10.2. South Korea.: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.5.10.3. South Korea: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.5.10.4. South Korea: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.6. Fibrate Drugs Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.6.2. Middle East & Africa: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.3. Middle East & Africa: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.6.4. Middle East & Africa: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.6.5. Fibrate Drugs Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.6.5.2. Saudi Arabia: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.5.3. Saudi Arabia: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.6.5.4. Saudi Arabia: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.6.6. Fibrate Drugs Market - South Africa
- 9.6.6.1. South Africa: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.6.6.2. South Africa: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.6.3. South Africa: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.6.6.4. South Africa: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.6.7. Fibrate Drugs Market - Israel
- 9.6.7.1. Israel: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.6.7.2. Israel: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.7.3. Israel: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.6.7.4. Israel: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.6.8. Fibrate Drugs Market - UAE
- 9.6.8.1. UAE: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.6.8.2. UAE: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.6.8.3. UAE: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.6.8.4. UAE: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.7. Fibrate Drugs Market - Latin America
- 9.7.1. Latin America: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.7.2. Latin America: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.3. Latin America: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.7.4. Latin America: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.7.5. Fibrate Drugs Market - Mexico
- 9.7.5.1. Mexico: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.7.5.2. Mexico: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.5.3. Mexico: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.7.5.4. Mexico: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.7.6. Fibrate Drugs Market - Brazil
- 9.7.6.1. Brazil: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.7.6.2. Brazil: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.6.3. Brazil: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.7.6.4. Brazil: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
- 9.7.7. Fibrate Drugs Market - Argentina
- 9.7.7.1. Argentina: Fibrate Drugs Market, by Drug, 2019-2032 (USD Billion)
- 9.7.7.2. Argentina: Fibrate Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
- 9.7.7.3. Argentina: Fibrate Drugs Market, by Product Type, 2019-2032 (USD Billion)
- 9.7.7.4. Argentina: Fibrate Drugs Market, by Form, 2019-2032 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. AbbVie Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Ajanta Pharma Inc
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. ANI Pharmaceuticals, Inc
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Aurobindo Pharma
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Cipla
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Lupin Pharmaceuticals, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Sun Pharmaceutical Industries Ltd.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Viatris Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Zydus Group
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
